Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP in the U.S.

Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. The introduction adds another life-saving treatment to Fresenius Kabi’s broad oncology portfolio that offers lower-cost options for treating a wide range of cancers.

For more information, please see the website of Fresenius Kabi.